Archive Adhoc- and Press releases 2013

ENGLISH DEUTSCH
07 November 2013
PR: WILEX regains US rights for RENCAREX® from Prometheus
10 October 2013
PR: WILEX publishes 9-month Financial Report 2013
06 September 2013
AH: Nuclea Biotechnologies Inc. acquires WILEX Inc. and extends their cooperation with WILEX AG
PR: Nuclea Biotechnologies Inc. acquires WILEX Inc. and extends their cooperation with WILEX AG
02 September 2013
PR: WILEX subsidiary Heidelberg Pharma signs license agreement for the development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche
07 August 2013
PR: WILEX starts clinical phase I trial with PI3K inhibitor WX-037
11 July 2013
PR: WILEX publishes half-yearly financial report 2013
10 July 2013
PR: UCB gets access to rights for an antibody programme from WILEX for non-oncology indications
02 July 2013
PR: Burrill Securities supports WILEX in exploring financing partners
03 June 2013
PR: Phase III ARISER data for the adjuvant treatment of clear cell renal cancer with RENCAREX® including retrospective subgroup analysis presented at ASCO
11 April 2013
PR: WILEX publishes 3-months financial report 2013
11 April 2013
PR: WILEX has been selected to give several presentations at ASCO
20 March 2013
PR: WILEX Inc. and Nuclea Biotechnologies Inc. announce cooperation
27 February 2013
PR: WILEX reports financial figures for financial year 2012
26 February 2013
PR: Subgroup analysis in the ARISER study shows significant improvement of disease free survival with RENCAREX®
31 January 2013
PR: WILEX Inc. and IBL-America sign non-exclusive marketing and distribution agreement for USA
23 January 2013
PR: WILEX Inc. and GeneDiagnostics Inc. enter into partnership for the IVD approval and distribution of the serum HER-2/neu test in China
Seite gelesen: 456 | Heute: 4